Celgene 4th-qtr profit falls on charges, revenue rises
Jan 24 (Reuters) - Drugmaker Celgene Corp on Thursday reported fourth-quarter net earnings that fell 35.8 percent after it took an acquisition-related charge.
Net income fell to $263.1 million, or 61 cents a share, from $410 million, or 91 cents a share, a year before. Revenue rose to $1.45 billion from $1.28 billion a year earlier on strong sales of its cancer drugs.
Excluding one-time items, the company earned $1.32 a share. Analysts on average had expected earnings of $1.31 a share, according to Thomson Reuters I/B/E/S. They had expected revenue of $1.46 billion.
(Reporting By Toni Clarke; Editing by Gerald E. McCormick)
Jan 24- Drugmaker Celgene Corp on Thursday reported fourth-quarter net earnings that fell 35.8 percent after it took an acquisition-related charge. Net income fell to $263.1 million, or 61 cents a share, from $410 million, or 91 cents a share, a year before. Revenue rose to $1.45 billion from $1.28 billion a year earlier on strong sales of its cancer drugs.